induced pluripotent stem cells

OAC1 (BAS 00287861) is a compound activating Octamer-binding transcription factor 4 (Oct4). It enhances the iPSC reprogramming efficiency and accelerates the reprogramming process.

OAC2 is an Oct4 activator which activates expression through the Oct4 gene promoter; enhances reprogramming efficiency by increasing the rate of production of induced pluripotent stem cells (iPSCs) from embryonic fibroblasts; an analog of OAC1.

MDI-114215 (compound 85) serves as an allosteric dual inhibitor of LIMK1/2 and exhibits favorable in vivo tolerance. It is capable of inhibiting the phosphorylation of cofilin in mouse brain region-induced pluripotent stem cells (iPSCs) and can be utilized in Fragile X Syndrome (FXS) research.

TTBK1/2-IN-3 (compound 10) is a potent inhibitor of Tau tubulin kinase 1 (TTBK1) and TTBK2, with IC50 values of 579 nM and 258 nM, respectively. TTBK1/2-IN-3 can reduce the expression of primary cilia on the surface of human induced pluripotent stem cells (iPSC).

TTBK1/2-IN-2 (compound 9) is a potent inhibitor of Tau tubulin kinase 1 (TTBK1) and TTBK2, with IC50 values of 384 nM and 175 nM, respectively. In human induced pluripotent stem cells (iPSC), TTBK1/2-IN-2 demonstrates a significant ciliogenesis phenotype.

Neuroprotective agent 13 is a 1H-benzimidazole [d] class compound with neuroprotective properties that can penetrate the blood-brain barrier. It activates autophagy (autophagy) and mitigates the accumulation of SCMAS in induced pluripotent stem cell (iPSC) derived neural progenitor cells. Neuroprotective agent 13 is applicable in the study of neurological disorders such as neuronal ceroid lipofuscinoses (NCLs).

Lipoxygenin is an inhibitor of 5-lipoxygenase (5-LO) with an IC50value of 5 μM for inhibition of 5-LO product synthesis in isolated human granulocytes stimulated with the cation ionophore A23187 .1It inhibits hedgehog-dependent signaling in Shh-LIGHT2 cells and TGF-β-, activin A-, bone morphogenic protein (BMP)-, or Wnt-dependent signaling in HEK293T cells (IC50s = 9.3, 3.2, 8.2, 9.6, and 3.7 μM, respectively, in luciferase reporter assays). Lipoxygenin (5 and 10 μM) increases levels of troponin T (TnnT), a marker of cardiomyocyte differentiation, in human induced pluripotent stem cells (iPSCs) stimulated with BMP4 and the glycogen synthase kinase 3 (GSK3) inhibitor CHIR99021 .

The methylation of lysine residues on histones plays a central role in determining euchromatin structure and gene expression. The histone methyltransferase (HMTase) G9a can mono- or dimethylate lysine 9 on histone 3 (H3), contributing to early embryogenesis, genomic imprinting, and lymphocyte development. BIX01294 (hydrochloride hydrate) is a selective inhibitor of G9a HMTase (IC50 = 1.7 μM). It less effectively inhibits the HMTase G9a-like protein (GLP; IC50 = 38 μM) and has no effect on other known HMTases. BIX01294 has been used in combination with the calcium channel activator BayK8644 to facilitate the generation of induced pluripotent stem cells from somatic cells in vitro.

NBD-LLLLpY is a peptide synthesized enzymatically within the nucleus to selectively target and eliminate human induced pluripotent stem cells (hiPSCs).

TCL065, an ionizable cationic lipid (pKa = 6.3), is utilized in the creation of lipid nanoparticles (LNPs) for the delivery of mRNA and single-guide RNA (sgRNA) both in vitro and in vivo. When LNPs with TCL065 encapsulate sgRNA targeting the donor site of dystrophin exon 45, along with those targeting the splicing acceptor site of dystrophin exon 45, dystrophin expression is restored in myoblasts derived from induced-pluripotent stem (iPS) cells from Duchenne muscular dystrophy (DMD) patients. Additionally, TCL065-containing LNPs encapsulating mRNA encoding Cas9 nuclease, combined with those containing sgRNA targeting the Rosa26 locus, have been applied for CRISPR-mediated gene editing in mouse gastrocnemius muscle.